Alemtuzumab is a monoclonal anti CD-52 antibody recently approved for use in relapsing-remitting multiple sclerosis(MS). Given that the targeted antigen is primarily expressed on B and T lymphocytes, the administration of this biological drug is associated with rapid but protracted peripheral lymphopenia.
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis / Buonomo, A. R.; Zappulo, E.; Viceconte, G.; Scotto, R.; Borgia, G.; Gentile, I.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 17:7(2018), pp. 709-717. [10.1080/14740338.2018.1483330]
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
Buonomo A. R.;Zappulo E.;Borgia G.;Gentile I.
2018
Abstract
Alemtuzumab is a monoclonal anti CD-52 antibody recently approved for use in relapsing-remitting multiple sclerosis(MS). Given that the targeted antigen is primarily expressed on B and T lymphocytes, the administration of this biological drug is associated with rapid but protracted peripheral lymphopenia.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Scala buonomo.pdf
non disponibili
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Licenza:
Accesso privato/ristretto
Dimensione
5.2 MB
Formato
Adobe PDF
|
5.2 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
